Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)

NCT03812679 | Terminated Results FDA Device

• 1 other identifier: BXU011787
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 11

Brief Summary

Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD). Complementary therapies offer longer term survival for patients with ESRD. However, none of them are devoid of side effects and today their limitations are better understood by the nephrologist. The AMIA APD Solution Generation System combines an updated AMIA APD Cycler with Sharesource Platform (previously cleared) with an in-home water system technology and leverages newly developed AMIA APD Concentrates. The AMIA APD Concentrates, after dilution by the AMIA APD Solution Generation System, are indicated for adult patients in acute or chronic renal failure when non-dialytic medical therapy is judged to be inadequate.

Conditions

End Stage Renal Disease (ESRD)

Outcome Measures

Primary Outcomes (3)

• Percentage of Tests Meeting Specifications for the Chemical Composition of Final Dialysis Solution by Visit

  The dialysis solution generated by the simulated treatment will be sampled from the heater bag, compared to the specifications of Baxter's approved low calcium Dianeal PD solution. The following 9 test methods will be analyzed: pH at 25 C, Color, 5- (hydroxymethyl)furfural (5HMF), Dextrose hydrous Assay (1.5%, 2.5% or 4.25%), Sodium Lactate Assay, Sodium Assay, Chloride Assay, Magnesium Chloride Hexahydrate (MgCl2.6H2O) Assay, and Calcium Chloride Dihydrate (CaCl2.2H2O) Assay. Measurements were collected using instruments such as meters, chromatography, etc. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications.

  Week 1, 4, 8 and 12

• Percentage of Tests Meeting Specifications for the Microbiological and Chemical Testing of Product Water From Water Device (Pre-sterilizing Filters) by Visit

  Microbiological testing within \<=0 CFU/mL limit for total aerobic microbial count (TAMC) and total yeast/mold count (TYMC) and \<0.03 EU/mL limit for Endotoxins, and chemical parameters. Product water from the WD (pre-sterilizing filters) was collected and tested for microbiological (including endotoxin) contamination per USP \<61\> and USP \<85\> and chemical contaminants according to ISO 13959. Chemical parameters include aluminum, copper, fluoride, lead, nitrate, sulphate, zinc, calcium, magnesium, potassium, sodium, antimony, arsenic, barium, beryllium, cadmium, chromium, mercury, selenium, silver, thallium, nickel, cobalt, total chlorine. Chemical measurements were collected using instruments such as meters, chromatography, etc. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications.

  Week 1, 4, 8 and 12

• Percentage of Tests Meeting Specifications for the Microbiological Testing of Product Water From Holding Bag (Post-sterilizing Filters) by Visit

  Microbiological testing within \<=0 CFU/mL limit for TAMC and TYMC and \<0.03 EU/mL limit for Endotoxins. Data will be reported showing percentage of participants meeting specifications versus percentage of participants not meeting specification. If any one of the values falls outside the limits, then the particular test is considered NOT meeting specifications. A test was considered as meeting specifications if all of the following parameters fell within the specified limits: tryptic soy broth growth, fluid thioglycolate growth, and endotoxins. Water in the holding bag was collected and tested for microbiological contamination and endotoxin levels per USP \<71\> and USP \<85\>.

  Week 1, 4, 8 and 12

Secondary Outcomes (1)

• Change From Baseline in Total Kt/Vurea at Week 5, 6, 7, or 8

  Baseline, Week 5 or Week 6 or Week 7 or Week 8

Study Arms (1)

AMIA APD Solution Generation System

EXPERIMENTAL

A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.

Device: AMIA APD Solution Generation System

Interventions

AMIA APD Solution Generation System DEVICE

The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).

AMIA APD Solution Generation System

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient is 18 years or older.
• Patient with ESRD receiving PD therapy, and who is already trained and regularly using the AMIA or HomeChoice APD Cycler with Dianeal PD Solution for at least 12 weeks.
• Patient is receiving or willing and able to use Dianeal Low Calcium (2.5 mEq/L) PD prescriptive regimen at study treatment initiation per Investigator's assessment.
• Patient demonstrates adequate PD therapy with clinical euvolemia as assessed by the Investigator with a total Kt/Vurea of a minimum of 1.7 within 45 days of Screening, or measured at Screening. If a total Kt/Vurea is not available within 45 days of Screening, it will be measured at Screening.
• Investigator assesses that, with appropriate training, the patient will be able to successfully manage his/her dialysis treatments with the AMIA APD Solution Generation System.
• Patient is available and is willing to complete training on the AMIA APD Solution Generation System.
• Patient and home environment are deemed suitable for treatment with the AMIA APD Solution Generation System, while in the home.
• Home electrical and water assessments meet suitability criteria for the AMIA APD Solution Generation System.
• The patient's home has suitable wireless connection or patient is willing to allow installation of suitable wireless connection.
• Patient and/or care partner (if participating) is able to read and understand English, and provide informed consent after an explanation of the proposed study. If the patient does not read and understand English, patient may still participate if he/she has a co-residing care partner who reads and understands English, assessed as adequate by the PI.
• Women of childbearing potential (not menopausal or surgically sterile) must not be pregnant. Serum qualitative and quantitative pregnancy test will be done within 14 days prior to initiation of study product.
• If qualitative serum β-hCG results are positive, repeat quantitative serum pregnancy test in 48 hours.
• If quantitative serum β-hCG levels show clinically significant rise within 48 hours, serum progesterone level should be taken. Serum progesterone \> 5 ng/mL will exclude a patient from the study.
• Sexually active males and females agree to use a reliable means of contraception during the study and for 30 days afterwards (e.g., oral contraceptive and condom, intrauterine device and condom, or diaphragm with spermicide and condom).

You may not qualify if:

• Patient with a history of PD catheter dysfunction within 12 weeks prior to study enrollment, as evaluated by the Investigator.
• Patient who had episodes of peritonitis or exit site infection within 12 weeks prior to study enrollment.
• Patient who has signs of impending or current infection including a cloudy dialysis effluent or dialysis white cell count \> 100/ μL or \> 0.1 x 109/ L (after a dwell time of at least 2 hours), with \> 50% polymorphonuclear cells, and/or positive dialysis effluent culture.
• Patient who has a severe primary immune deficiency or other condition that may mask clinical signs of peritonitis, as evaluated by the Investigator.
• Patient with a history of repeated non-compliance with PD, therapy (e.g., a substantial number of missed clinic visits, missed treatments or a history of mismanagement of diet or medications), as evaluated by the Investigator.
• Patient who has acute renal failure with the chance for recovery.
• Patient who is pre-scheduled for a living donor kidney transplant within the next 6 months.
• Patient who is not expected to live at least 6 months while maintaining PD treatment.
• Patient who had major abdominal surgery within 6 months prior to study enrollment.
• Patient with current abdominal hernia, as evaluated by the Investigator.
• Patient with advanced liver or pulmonary disease, as evaluated by the Investigator.
• Positive serology test for Hepatitis B Virus or Hepatitis C Virus infection, or aspartate transaminase or alanine aminotransferase \> 3 x upper limit of normal at Screening.
• Patient with diagnosed stage III or IV New York Heart Association (NYHA) heart failure.
• Patient who has an active malignancy.
• History of a clinically significant illness and/or clinically significant surgery within the past 14 days preceding the Screening Visit as determined by the Investigator.

Sponsors & Collaborators

• Vantive Health LLC: lead
• Baxter Healthcare Corporation: collaborator

Study Sites (11)

Investigational Site

Jonesboro, Arkansas, 72401, United States

Location

Investigational Site

San Jose, California, 95125, United States

Location

Investigational Site

Jacksonville, Florida, 32224, United States

Location

Investigational Site

Chicago, Illinois, 60612, United States

Location

Investigational Site

Ann Arbor, Michigan, 48104, United States

Location

Investigational Site

Jackson, Mississippi, 39213, United States

Location

Investigational Site

New York, New York, 10021, United States

Location

Investigational Site

New York, New York, 10029, United States

Location

Investigational Site

Cleveland, Ohio, 44106, United States

Location

Investigational Site

Temple, Texas, 76508, United States

Location

Investigational Site

Fitchburg, Wisconsin, 53713, United States

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Limitations and Caveats

The study was terminated for business reasons not due to scientific data. Sufficient data was acquired to transition program development to other technologies. All enrolled subjects had completed treatment at the time that the US was impacted by COVID-19.

Results Point of Contact

• Title: Global CORP Clinical Trials Disclosure
• Organization: Vantive

Global.CORP.ClinicalTrialsDisclosure@vantive.com

+1 2249484283

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2019
• First Posted: January 23, 2019
• Study Start: December 20, 2018
• Primary Completion: February 19, 2020
• Study Completion: February 19, 2020
• Last Updated: July 14, 2025
• Results First Posted: February 5, 2021

Record last verified: 2025-07

Locations

US (11)